CN106102735A - 瘤形成的治疗 - Google Patents

瘤形成的治疗 Download PDF

Info

Publication number
CN106102735A
CN106102735A CN201580015101.9A CN201580015101A CN106102735A CN 106102735 A CN106102735 A CN 106102735A CN 201580015101 A CN201580015101 A CN 201580015101A CN 106102735 A CN106102735 A CN 106102735A
Authority
CN
China
Prior art keywords
dose
patient
treatment
oxa
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580015101.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·卡德
M·塔普纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtex Medical Pty Ltd
Original Assignee
Sirtex Medical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900232A external-priority patent/AU2014900232A0/en
Application filed by Sirtex Medical Pty Ltd filed Critical Sirtex Medical Pty Ltd
Publication of CN106102735A publication Critical patent/CN106102735A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580015101.9A 2014-01-24 2015-01-23 瘤形成的治疗 Pending CN106102735A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014900232A AU2014900232A0 (en) 2014-01-24 Treatment of Neoplasia
AU2014900232 2014-01-24
PCT/AU2015/000037 WO2015109367A1 (en) 2014-01-24 2015-01-23 Treatment of neoplasia

Publications (1)

Publication Number Publication Date
CN106102735A true CN106102735A (zh) 2016-11-09

Family

ID=53680513

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015101.9A Pending CN106102735A (zh) 2014-01-24 2015-01-23 瘤形成的治疗

Country Status (12)

Country Link
US (1) US10849900B2 (2)
EP (1) EP3096752B1 (2)
JP (1) JP2017503846A (2)
KR (1) KR102317751B1 (2)
CN (1) CN106102735A (2)
AU (1) AU2015208666B2 (2)
BR (1) BR112016016932A8 (2)
CA (1) CA2937015C (2)
IL (1) IL246880B (2)
PH (1) PH12016501407A1 (2)
SG (1) SG11201605900VA (2)
WO (1) WO2015109367A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107246A1 (en) * 2016-12-16 2018-06-21 The Australian National University Improving selective internal radiation therapy
US10992078B2 (en) 2018-01-29 2021-04-27 Bard Access Systems, Inc. Connection system for establishing an electrical connection through a drape and methods thereof
WO2019221926A1 (en) 2018-05-18 2019-11-21 Bard Access Systems, Inc. Connection systems and methods thereof for establishing an electrical connection through a drape
US11622675B2 (en) 2019-05-15 2023-04-11 Boston Scientific Scimed, Inc. Medical device having asymmetric bending
CA3146657A1 (en) 2019-07-12 2021-01-21 Bard Access Systems, Inc. Catheter tracking and placement system including light emitting diode array
US12029498B2 (en) 2019-08-08 2024-07-09 Bard Access Systems, Inc. Optical-fiber connector modules including shape-sensing systems and methods thereof
EP4355418A1 (en) * 2021-06-14 2024-04-24 Novocure GmbH Methods of treating and preventing cancer with alternating electric fields, radioactive particles, and systemic therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002629A1 (en) * 2003-07-02 2005-01-13 Sirtex Medical Limited Combination therapy of oxaliplatin and radioactively doped particles treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6379648B1 (en) 1999-02-01 2002-04-30 The Curators Of The University Of Missouri Biodegradable glass compositions and methods for radiation therapy
WO2000045826A1 (en) 1999-02-02 2000-08-10 The Curators Of The University Of Missouri Process for making ceramic microspheres
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
AUPR098200A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Production of low density radionuclide containing microspheres
US20110160159A1 (en) * 2009-09-15 2011-06-30 John Ryan Treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002629A1 (en) * 2003-07-02 2005-01-13 Sirtex Medical Limited Combination therapy of oxaliplatin and radioactively doped particles treating cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BENNETT PLUM 总主编: "《西塞尔内科学》", 30 June 1999, 世界图书出版西安公司 *
DUTTON, S.J. ET AL: "FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional", 《BMC CANCER》 *
GIBBS, P. ET AL: ""Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorecta cancer: the SIRFLOX study", 《BMC CANCER》 *
GULEC, S.A: "Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial", 《AM J CLIN ONCOL》 *
HREHORET, D. ET AL: "HREHORET, D. et al", 《CHIRURGIA》 *
SHARMA, R.A. ET AL: "FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer", 《CLIN ONCOL》 *
SHARMA, R.A. ET AL: "Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil,and leucovorin chemotherapy", 《J CLIN ONCOL》 *
VENTE, M. A. ET AL: "Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a stmctured meta-analysis", 《EUR RADIOL》 *
王吉甫主编: "《胃肠外科学》", 31 October 2000, 人民卫生出版社 *
陶国枢,何慧德主编: "《现代老年医学答疑》", 30 September 1996, 军事医学科学出版社 *

Also Published As

Publication number Publication date
EP3096752A4 (en) 2017-10-18
CA2937015C (en) 2022-08-02
KR20160122142A (ko) 2016-10-21
AU2015208666A1 (en) 2016-09-01
JP2017503846A (ja) 2017-02-02
IL246880B (en) 2021-10-31
BR112016016932A2 (pt) 2017-08-08
CA2937015A1 (en) 2015-07-30
KR102317751B1 (ko) 2021-10-27
US20170000795A1 (en) 2017-01-05
PH12016501407A1 (en) 2016-08-31
AU2015208666B2 (en) 2019-08-22
EP3096752B1 (en) 2026-03-18
US10849900B2 (en) 2020-12-01
NZ723150A (en) 2021-05-28
SG11201605900VA (en) 2016-08-30
BR112016016932A8 (pt) 2020-06-16
EP3096752A1 (en) 2016-11-30
WO2015109367A1 (en) 2015-07-30
IL246880A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
CN106102735A (zh) 瘤形成的治疗
Goyal et al. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
AU2015255622B2 (en) Method for treating renal cell carcinoma
AU2013315276A1 (en) Method of treating cancer
US20060115424A1 (en) Combination therapy of oxaliplatin and radioactively doped particles treating cancer
US20040220135A1 (en) Combination therapy for treatment of neoplasia
US10232063B2 (en) Method for treating lung carcinoma
AU2014203772B2 (en) Method for Treating Lung Carcinoma
US20250249133A1 (en) Radioembolic beads and methods for treatment of tumor cells
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
NZ723150B2 (en) Treatment of neoplasia
JP2018514586A (ja) 癌の治療のための組成物
HK40092801A (zh) 用於治疗癌症的纳米颗粒组合物
WO2006002488A1 (en) Combination therapy for treatment of neoplasia
Day Glass Microspheres for Cancer Treatment
HK1230494B (en) Microparticles for treating renal cell carcinoma
HK1230494A1 (en) Microparticles for treating renal cell carcinoma
AU2003203953A1 (en) Combination Therapy for Treatment of Neoplasia
CA2856389A1 (en) Method for treating lung carcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination